𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa

✍ Scribed by Rascol, Olivier; Brooks, David J.; Korczyn, Amos D.; De Deyn, Peter P.; Clarke, Carl E.; Lang, Anthony E.

Book ID
120000778
Publisher
Massachusetts Medical Society
Year
2000
Tongue
English
Weight
114 KB
Volume
342
Category
Article
ISSN
0096-6762

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Onset of dyskinesia with adjunct ropinir
Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease
✍ Ray L. Watts; Kelly E. Lyons; Rajesh Pahwa; Kapil Sethi; Matthew Stern; Robert A πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 135 KB πŸ‘ 1 views

Levodopa-induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD). The goal of this study was to determine if the addition of once-daily ropinirole 24hour prolonged-release (n 5 104) in PD patients not optimally controll

Ropinirole in the treatment of early Par
Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study
✍ Dr. Olivier Rascol; David J. Brooks; Ehrout R. Brunt; Amos D. Korczyn; Warner H. πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 785 KB

The efficacies of ropinirole and levodopa were compared after 6 months of treatment in a planned interim analysis of a 5-year, double-blind, randomized, multicenter study of patients with early Parkinson's disease requiring dopaminergic therapy. The percentage of improvement in the Unified Parkinson

A comparison of sumanirole versus placeb
A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease
✍ Carlos Singer; Janice Lamb; Amanda Ellis; Gary Layton πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 146 KB πŸ‘ 1 views

## Abstract To assess the safety and efficacy of sumanirole, a highly selective dopamine agonist, versus placebo and demonstrate its noninferiority to ropinirole, 614 patients with early Parkinson's disease (PD) were treated with sumanirole, 1 to16 mg/day; ropinirole, 0.75 to 24 mg/day; or placebo.